La nostra pipeline

Ultimo aggiornamento, luglio 2023.

Molecule / Project
Indication
Expected Launch
Preclinical Phase Phase I Phase II Phase III Under Registration Geography
Lebrikizumab Atopic dermatitis Late 2023
90 Under registration
EU EU
Tirbanibulin
Extended label		 Actinic keratosis US 2024 / EU 2026
75 Fase3
U.S. U.S.
EU EU
Sarecycline Acne 2024
80 Fase3
China China
Efinaconazole Onychomycosis 2023
95 Under registration
EU EU
Anti-IL-1RAP mAb Autoinmune dermatology TBD
30 Fase1
Worldwide Worldwide
IL-2 mu Fc Autoinmune dermatology TBD
15 Preclinical Phase
Worldwide Worldwide*

Atopic dermatitis Lebrikizumab Late 2023 Under registration EU

Actinic keratosis Tirbanibulin
Extended label US 2024 / EU 2026 Fase3 U.S. EU

Acne Sarecycline 2024 Fase3 china

Onychomycosis Efinaconazole 2023 Under registration EU

Autoinmune dermatology Anti-IL-1RAP mAb TBD Fase1 worldwide

Autoinmune dermatology IL-2 mu Fc TBD Preclinical Phase worldwide_exchina ‏‏* Worldwide ex-Greater China